Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.47 |
| ▸ | LSS | P48449 | 2/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218475 | 0.95 | HTR3A (0.59) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL8125540 | 0.92 | HTR3A (0.57) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL22870548 | 0.92 | HTR3A (0.57) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL127746 | 0.92 | HTR3A (0.57) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL315186 | 0.89 | HTR3A (0.58) | HTR3ADRD2SLC18A3ESR2LSS | |
| Bicarbonate SCHEMBL11118762 | 0.89 | BCL2L1 (0.50) | HTR3ADRD2SLC18A3ALDH1A1POLB | |
| SCHEMBL8747330 | 0.89 | HTR3A (0.50) | HTR3ADRD2SLC18A3ESR2MEN1 | |
| Methyl Alcohol SCHEMBL8471414 | 0.88 | SLC18A3 (0.56) | HTR3ADRD2SLC18A3ESR2LSS | |
| SCHEMBL11492945 | 0.87 | BCL2L1 (0.49) | HTR3ASLC18A3 | |
| SCHEMBL12917876 | 0.86 | HTR3A (0.52) | HTR3ADRD2SLC18A3ESR2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| JP-4789934-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | claimed |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2008-02-21 | — | — | US | claimed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1753736-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | claimed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| WO-2002036540-A2 | PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE | TORRENT PHARMACEUTICALS LTD (IN) | 2002-05-10 | — | — | WO | claimed |
| EP-0230742-B1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1990-09-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | HTR3A 937/4885DRD2 1476/4885SLC18A3 2946/4885 |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | HTR3A 1500/4885DRD2 1660/4885SLC18A3 3409/4885 |
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | HTR3A 930/4885DRD2 941/4885SLC18A3 2731/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | HTR3A 3957/4885DRD2 4873/4885SLC18A3 2346/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | HTR3A 1500/4885DRD2 1660/4885SLC18A3 3409/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | HTR3A 937/4885DRD2 1476/4885SLC18A3 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.